These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24126707)

  • 1. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females.
    Clarke TK; Crist RC; Ang A; Ambrose-Lanci LM; Lohoff FW; Saxon AJ; Ling W; Hillhouse MP; Bruce RD; Woody G; Berrettini WH
    Pharmacogenomics J; 2014 Jun; 14(3):303-8. PubMed ID: 24126707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.
    Crist RC; Clarke TK; Ang A; Ambrose-Lanci LM; Lohoff FW; Saxon AJ; Ling W; Hillhouse MP; Bruce RD; Woody G; Berrettini WH
    Neuropsychopharmacology; 2013 Sep; 38(10):2003-10. PubMed ID: 23612435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence.
    Crist RC; Doyle GA; Nelson EC; Degenhardt L; Martin NG; Montgomery GW; Saxon AJ; Ling W; Berrettini WH
    Pharmacogenomics J; 2018 Jan; 18(1):173-179. PubMed ID: 27958381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder.
    Kranzler HR; Lynch KG; Crist RC; Hartwell E; Le Moigne A; Laffont CM; Andorn AC
    Int J Neuropsychopharmacol; 2021 Feb; 24(2):89-96. PubMed ID: 32920647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OPRD1 rs569356 polymorphism has an effect on plasma norbuprenorphine levels and dose/kg-normalized norbuprenorphine values in individuals with opioid use disorder.
    Kaya-Akyüzlü D; Özkan-Kotiloğlu S; Danışman M; Bal C; Oğur B; İspir GZ
    Environ Toxicol Pharmacol; 2023 Jun; 100():104143. PubMed ID: 37146669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations.
    Crist RC; Ambrose-Lanci LM; Vaswani M; Clarke TK; Zeng A; Yuan C; Ferraro TN; Hakonarson H; Kampman KM; Dackis CA; Pettinati HM; O'Brien CP; Oslin DW; Doyle GA; Lohoff FW; Berrettini WH
    Drug Alcohol Depend; 2013 Jan; 127(1-3):122-8. PubMed ID: 22795689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An analysis of genetic association in opioid dependence susceptibility.
    Nagaya D; Zahari Z; Saleem M; Yahaya BH; Tan SC; Yusoff NM
    J Clin Pharm Ther; 2018 Feb; 43(1):80-86. PubMed ID: 28656735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the existing literature on buprenorphine pharmacogenomics.
    Meaden CW; Mozeika A; Asri R; Santos CD
    Pharmacogenomics J; 2021 Apr; 21(2):128-139. PubMed ID: 33154520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
    Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients.
    Thomas PS; Nielsen EM; Spellicy CJ; Harding MJ; Ye A; Patriquin M; Hamon SC; Kosten TR; Nielsen DA
    Psychiatr Genet; 2021 Jun; 31(3):88-94. PubMed ID: 33953123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of SNP-SNP interaction among ABCB1, ARRB2, DRD1 and OPRD1 on methadone dosage requirement in Han Chinese patients.
    Luo R; Li X; Qin S; Luo Z; Luo X; Hu P; Liu Z; Feng X; Li X
    Pharmacogenomics; 2017 Dec; 18(18):1659-1670. PubMed ID: 29173032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid agonist treatment for pharmaceutical opioid dependent people.
    Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N
    Cochrane Database Syst Rev; 2016 May; (5):CD011117. PubMed ID: 27157143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study.
    Beer B; Erb R; Pavlic M; Ulmer H; Giacomuzzi S; Riemer Y; Oberacher H
    PLoS One; 2013; 8(9):e75359. PubMed ID: 24086514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder.
    Crist RC; Phillips KA; Furnari MA; Moran LM; Doyle GA; McNicholas LF; Cornish JW; Kampman KM; Preston KL; Berrettini WH
    Pharmacogenomics J; 2019 Jun; 19(3):260-268. PubMed ID: 30368523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.
    Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P
    JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment.
    Barbosa-Leiker C; McPherson S; Layton ME; Burduli E; Roll JM; Ling W
    Am J Drug Alcohol Abuse; 2018; 44(4):488-496. PubMed ID: 29672167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
    Otiashvili D; Piralishvili G; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    Drug Alcohol Depend; 2013 Dec; 133(2):376-82. PubMed ID: 23916321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A delta-opioid receptor genetic variant is associated with abstinence prior to and during cocaine dependence treatment.
    Crist RC; Doyle GA; Kampman KM; Berrettini WH
    Drug Alcohol Depend; 2016 Sep; 166():268-71. PubMed ID: 27449273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.